{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:43:59Z","timestamp":1787496239745,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The prognosis of pancreatic ductal carcinoma (PDAC) with peritoneal metastasis remains dismal. Systemic chemotherapy alone may not be effective, and the combination of intraperitoneal chemotherapy with systemic chemotherapy is expected to prolong the overall survival in patients with peritoneal metastasis. We have designed a randomized phase III trial to confirm the superiority of intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel (PTX) with S-1 relative to gemcitabine plus nab-PTX (GnP), which is the current standard therapy for patients with metastatic PDAC. A total of 180 patients will be accrued from 30 institutions within 3 years. Patients will be randomly assigned in a 1:1 ratio to receive either i.v. and i.p. PTX with S-1 or GnP (target of 90 patients per group). The primary endpoint is overall survival; secondary endpoints are progression-free survival, response rate, proportion with negative peritoneal washing cytology during chemotherapy, proportion requiring conversion surgery, and adverse event profiles. Japan Registry of Clinical Trials jRCTs051180199 (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/jrct.niph.go.jp\/\">https:\/\/jrct.niph.go.jp\/<\/jats:ext-link>\n                    ).\n                  <\/jats:p>","DOI":"10.1186\/s13063-022-06049-7","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T07:02:29Z","timestamp":1644044549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)"],"prefix":"10.1186","volume":"23","author":[{"given":"Tomohisa","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuhiko","family":"Motoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goro","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Unno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yamaue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Yamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Yoshitomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsugu","family":"Sekimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6527-5409","authenticated-orcid":false,"given":"Sohei","family":"Satoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Study Group of Pancreatic Ductal Adenocarcinoma with Peritoneal Metastasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,5]]},"reference":[{"key":"6049_CR1","unstructured":"Matsuda T, Ajiki W, Marugame T, et al. Monitoring of cancer incidence in Japan - Survival 2009-2011 Report. Tokyo: Center for Cancer Control and Information Services, National Cancer Center; 2020."},{"issue":"6","key":"6049_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S1091-255X(00)80105-5","volume":"4","author":"TA Sohn","year":"2000","unstructured":"Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas in 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567\u201379. https:\/\/doi.org\/10.1016\/S1091-255X(00)80105-5.","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"6049_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/00000658-199905000-00012","volume":"229","author":"KD Lillemoe","year":"1999","unstructured":"Lillemoe KD, Kaushal S, Cameron JL, Sohn TA, Pitt HA, Yeo CJ. Distal pancreatectomy: indications and outcomes in 235 patients. Ann Surg. 1999;229(5):693\u20138. https:\/\/doi.org\/10.1097\/00000658-199905000-00012.","journal-title":"Ann Surg"},{"issue":"18","key":"6049_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"issue":"19","key":"6049_CR5","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"issue":"3","key":"6049_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/MPA.0000000000000290","volume":"44","author":"N Takahara","year":"2015","unstructured":"Takahara N, Isayama H, Nakai Y, Sasaki T, Saito K, Hamada T, et al. Pancreatic cancer with malignant ascites. Pancreas. 2015;44(3):380\u20135. https:\/\/doi.org\/10.1097\/MPA.0000000000000290.","journal-title":"Pancreas"},{"issue":"1","key":"6049_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/MPA.0b013e31825abf8c","volume":"42","author":"I Thomassen","year":"2013","unstructured":"Thomassen I, Lemmens VE, Nienhuijs SW, et al. Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study. Pancreas. 2013;42(1):72\u20135. https:\/\/doi.org\/10.1097\/MPA.0b013e31825abf8c.","journal-title":"Pancreas"},{"issue":"1","key":"6049_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343. https:\/\/doi.org\/10.1056\/NEJMoa052985.","journal-title":"N Engl J Med"},{"issue":"1","key":"6049_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/annonc\/mdp260","volume":"21","author":"H Ishigami","year":"2010","unstructured":"Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21(1):67\u201370. https:\/\/doi.org\/10.1093\/annonc\/mdp260.","journal-title":"Ann Oncol"},{"issue":"2","key":"6049_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/jjco\/hyq187","volume":"41","author":"Y Kodera","year":"2011","unstructured":"Kodera Y, Imano M, Yoshikawa T, Takahashi N, Tsuburaya A, Miyashita Y, et al. A randomized phase II trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (INPACT trial). Jpn J Clin Oncol. 2011;41(2):283\u20136. https:\/\/doi.org\/10.1093\/jjco\/hyq187.","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"6049_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s12029-014-9603-1","volume":"45","author":"N Takahara","year":"2014","unstructured":"Takahara N, Isayama H, Nakai Y, Sasaki T, Ishigami H, Yamashita H, et al. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. J Gastrointest Cancer. 2014;45(3):307\u201311. https:\/\/doi.org\/10.1007\/s12029-014-9603-1.","journal-title":"J Gastrointest Cancer"},{"issue":"1","key":"6049_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1349-7006.2010.01747.x","volume":"102","author":"T Kamei","year":"2011","unstructured":"Kamei T, Kitayama J, Yamaguchi H, Soma D, Emoto S, Konno T, et al. Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules. Cancer Sci. 2011;102(1):200\u20135. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01747.x.","journal-title":"Cancer Sci"},{"issue":"8","key":"6049_CR13","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","volume":"15","author":"MA Tempero","year":"2017","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(8):1028\u201361. https:\/\/doi.org\/10.6004\/jnccn.2017.0131.","journal-title":"J Natl Compr Canc Netw."},{"issue":"2","key":"6049_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/SLA.0000000000001705","volume":"265","author":"S Satoi","year":"2017","unstructured":"Satoi S, Fujii T, Yanagimoto H, Motoi F, Kurata M, Takahara N, et al. Multicenter phase II study of intravenous and intraperitoneal paclitaxel with S-1 for pancreatic ductal adenocarcinoma patients with peritoneal metastasis. Ann Surg. 2017;265(2):397\u2013401. https:\/\/doi.org\/10.1097\/SLA.0000000000001705.","journal-title":"Ann Surg."},{"issue":"2","key":"6049_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"3","key":"6049_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol: A new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9.","journal-title":"Health Policy"},{"issue":"5","key":"6049_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"6049_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12957-016-0767-y","volume":"14","author":"S Satoi","year":"2016","unstructured":"Satoi S, Yanagimoto H, Yamamoto T, Toyokawa H, Hirooka S, Yamaki S, et al. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic cancer. World J Surg Oncol. 2016;14(1):14. https:\/\/doi.org\/10.1186\/s12957-016-0767-y.","journal-title":"World J Surg Oncol"},{"issue":"10041","key":"6049_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(16)30583-9.","journal-title":"Lancet"},{"issue":"8","key":"6049_CR20","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/jjco\/hyq059","volume":"40","author":"Y Nakai","year":"2010","unstructured":"Nakai Y, Isayama H, Sasaki T, Sasahira N, Kogure H, Hirano K, et al. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. Jpn J Clin Oncol. 2010;40(8):774\u201380. https:\/\/doi.org\/10.1093\/jjco\/hyq059.","journal-title":"Jpn J Clin Oncol"},{"issue":"13","key":"6049_CR21","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","volume":"31","author":"H Ueno","year":"2013","unstructured":"Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31(13):1640\u20138. https:\/\/doi.org\/10.1200\/JCO.2012.43.3680.","journal-title":"J Clin Oncol"},{"issue":"3","key":"6049_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000012099","volume":"58","author":"W Koizumi","year":"2000","unstructured":"Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58(3):191\u20137. https:\/\/doi.org\/10.1159\/000012099.","journal-title":"Oncology"},{"issue":"2","key":"6049_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000067774","volume":"64","author":"T Mori","year":"2003","unstructured":"Mori T, Fujiwara Y, Yano M, Tamura S, Yasuda T, Takiguchi S, et al. Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-fluorouracil. Oncology. 2003;64(2):176\u201382. https:\/\/doi.org\/10.1159\/000067774.","journal-title":"Oncology"},{"issue":"9","key":"6049_CR24","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3748\/wjg.v12.i9.1412","volume":"12","author":"M Kobayashi","year":"2006","unstructured":"Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, et al. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol. 2006;12(9):1412\u20135. https:\/\/doi.org\/10.3748\/wjg.v12.i9.1412.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"6049_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/jhbp.447","volume":"24","author":"S Satoi","year":"2017","unstructured":"Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Yamaki S, Kosaka H, et al. Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospective study in a single institution. J Hepatobiliary Pancreat Sci. 2017;24(5):289\u201396. https:\/\/doi.org\/10.1002\/jhbp.447.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"13","key":"6049_CR26","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/bjs.11792","volume":"107","author":"S Yamada","year":"2020","unstructured":"Yamada S, Fujii T, Yamamoto T, Takami H, Yoshioka I, Yamaki S, et al. Phase I\/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Br J Surg. 2020;107(13):1811\u20137. https:\/\/doi.org\/10.1002\/bjs.11792.","journal-title":"Br J Surg"},{"issue":"19","key":"6049_CR27","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC Trial. J Clin Oncol. 2018;36(19):1922\u20139. https:\/\/doi.org\/10.1200\/JCO.2018.77.8613.","journal-title":"J Clin Oncol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06049-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06049-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06049-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T07:08:47Z","timestamp":1644044927000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06049-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,5]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6049"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06049-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-566893\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,5]]},"assertion":[{"value":"26 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of Wakayama Medical University approved the research protocol ver. 1 on September 5, 2019. This trial complies with the principles of the Declaration of Helsinki. Written informed consent will be obtained from all participants","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}